The American Academy of Dermatology (AAD) updates its acne management guidelines regularly because dermatological science is constantly advancing. New research emerges about treatment effectiveness, safety risks, and how acne responds to different medications. The most significant recent update occurred on January 31, 2024, when the AAD published comprehensive revised guidelines in the Journal of the American Academy of Dermatology, replacing the 2016 version.
These updates happen because what dermatologists know about treating acne—and what works best for different patients—changes as clinical evidence accumulates, new medications become available, and physicians gain better understanding of both the benefits and risks of existing treatments. Guidelines get revised roughly every 7-10 years because that’s typically how long it takes for sufficient new research to accumulate and for the medical community to identify meaningful shifts in practice. The 2024 update, which now covers patients ages 9 and older, contains 18 specific evidence-based recommendations and 5 good practice statements—a more structured and detailed approach than what existed eight years prior. This article explains why these updates matter, what drives the revision process, and how the latest guidelines reflect our evolved understanding of acne treatment.
Table of Contents
- What Changes in Acne Science Trigger Guideline Updates?
- How Do Safety Concerns Shape Guideline Changes?
- What Does the 2024 AAD Acne Guideline Update Actually Include?
- Why Strong First-Line Recommendations Matter for Treatment Decisions
- The Role of Antibiotic Stewardship in Modern Acne Guidelines
- What the Evidence Gaps Tell Us About Future Research Needs
- How Guidelines Will Continue Evolving
- Conclusion
What Changes in Acne Science Trigger Guideline Updates?
Medical guidelines are living documents that shift as the evidence base grows. Between 2016 and 2024, dermatologists and acne researchers published thousands of new studies examining everything from how topical medications work on acne-prone skin to the long-term safety profiles of systemic treatments. When enough evidence accumulates that contradicts or strengthens previous recommendations, the medical organizations responsible for guidelines convene expert committees to review the data and decide whether recommendations need adjustment. Sometimes new drugs come to market, or existing medications gain new applications. Other times, safety concerns emerge that require recommendations to change—and antibiotic resistance is a perfect example of this phenomenon. The revision process is methodical and evidence-focused.
Dermatologists on the guideline committee don’t simply update recommendations based on clinical intuition or what they’ve observed in their practices. Instead, they conduct systematic reviews of published research, evaluate the quality and strength of evidence for each treatment, and reach consensus on what the data actually supports. This is why the 2024 guidelines distinguish between “strong recommendations” (backed by robust evidence) and “good practice statements” (based on clinical experience when strong evidence is limited). For instance, benzoyl peroxide and topical retinoids earned strong recommendations as first-line treatments because the evidence supporting their effectiveness is particularly solid. New patient populations or previously overlooked demographics can also prompt guideline updates. The expanded age range in the 2024 guidelines—now explicitly addressing children ages 9 and older—reflects growing recognition that acne doesn’t start at puberty for every patient and that younger children sometimes need evidence-based treatment options. Previous guidance didn’t specifically address this group, so updating the guidelines to include them made the recommendations more practical for real-world dermatology.
How Do Safety Concerns Shape Guideline Changes?
One of the most important reasons guidelines change is when evidence reveals that a previously recommended treatment carries unexpected risks. A clear example is the 2024 guidance on oral doxycycline. Doxycycline is a strong antibiotic that works against the bacteria causing acne, and previous guidelines recommended it fairly liberally for moderate acne. However, widespread antibiotic use has contributed to antibiotic resistance—a major public health problem where bacteria evolve to survive antibiotics, making these medications less effective over time. The 2024 guidelines now strongly recommend doxycycline for acne treatment, which may seem counterintuitive, but with a critical caveat: the use should be carefully limited and considered within the broader context of reducing unnecessary antibiotic resistance. This type of shift demonstrates why regular updates are essential.
Ten years ago, the resistance problem wasn’t as widely understood or quantified. As research accumulated showing links between unnecessary antibiotic prescribing and resistance patterns, professional organizations had to weigh the benefit of treating individual patients against the population-level harm of overusing antibiotics. The updated guidelines reflect this ethical and scientific tension. If the AAD didn’t update its guidance regularly, dermatologists would continue following outdated recommendations that ignore these safety developments. However, limiting doxycycline use doesn’t mean acne patients with moderate disease have fewer options. The guidelines maintain strong support for other treatments—like topical retinoids and benzoyl peroxide combinations—that can effectively manage many cases without systemic antibiotics. This is why the guidelines emphasize thoughtful treatment selection rather than simply ruling options out.
What Does the 2024 AAD Acne Guideline Update Actually Include?
The January 2024 update introduced 18 evidence-based recommendations and 5 good practice statements that cover the full spectrum of acne treatment approaches. For most patients with mild to moderate acne, the guidelines recommend starting with topical treatments. Benzoyl peroxide and topical retinoids (medications that increase skin cell turnover) are identified as first-line options because they address acne through different mechanisms: benzoyl peroxide reduces acne-causing bacteria while retinoids normalize skin shedding. A particularly useful good practice statement in the 2024 guidelines recommends combining multiple topical treatment mechanisms—meaning using different active ingredients together—because combining approaches typically produces better results than using a single treatment alone. For patients whose acne doesn’t respond adequately to topical treatments, the guidelines support oral medications. Oral doxycycline remains a recommended choice for moderate acne, though with the antibiotic resistance considerations mentioned earlier.
For more severe cases—particularly acne that causes psychological distress, threatens to scar the skin, or fails standard oral and topical therapy—the guidelines recommend considering oral isotretinoin (commonly known by the brand name Accutane). Isotretinoin is a potent medication that can produce long-term remission or cure of acne, but it carries significant risks and requires careful monitoring, so it’s reserved for the most difficult cases. One notable aspect of the 2024 update is what didn’t make the cut for formal recommendations. The guidelines note that chemical peels, laser and light-based therapies, microneedling, dietary modifications, and plant-based acne products all lacked sufficient evidence for the committee to make formal recommendations. This doesn’t mean these treatments never work—it means the research either hasn’t been conducted at high enough quality or at sufficient scale to warrant guideline-level endorsement. Some dermatologists may still offer these treatments, but they do so based on clinical experience rather than guideline backing.
Why Strong First-Line Recommendations Matter for Treatment Decisions
When guidelines identify specific medications as “strong recommendations” versus “good practice” versus “insufficient evidence,” they’re creating a hierarchy that helps both doctors and patients make efficient treatment decisions. Strong recommendations for benzoyl peroxide and topical retinoids exist because decades of research confirm their effectiveness and safety profiles. A patient starting acne treatment doesn’t need to try 10 different products; the guidelines help narrow the field to what evidence suggests will most likely work. This speeds up the path to clear skin. Knowing what’s strongly recommended also helps patients understand why their dermatologist might recommend a particular treatment. If a doctor suggests a topical retinoid, it’s not because it’s trendy or because the company marketing it is effective—it’s because the AAD, after reviewing all available evidence, determined it’s a first-line option.
The same applies to benzoyl peroxide, which has been around for decades and remains foundational in acne care. When new patients ask “Why are you recommending this instead of that?” the answer often points back to guideline recommendations based on evidence. However, guidelines also acknowledge that patients are individuals. While benzoyl peroxide works well for many people, others experience irritation or dryness. While topical retinoids are effective, they can cause initial flaking and photosensitivity. The good practice statements recognize this reality—they note that combining multiple mechanisms is often better than relying on a single approach, and they implicitly acknowledge that treatment selection should account for a patient’s skin type, tolerance, and previous experiences.
The Role of Antibiotic Stewardship in Modern Acne Guidelines
Antibiotic stewardship—the careful, deliberate use of antibiotics only when truly necessary—has become central to how dermatologists manage acne in 2024 and beyond. This represents a significant shift in emphasis from earlier guidelines. Twenty years ago, oral antibiotics were often prescribed liberally for acne without much consideration for broader resistance implications. Today’s dermatologists understand they’re not just treating the patient in front of them; they’re contributing to either the problem of antibiotic resistance or the solution. The 2024 guidelines address this by recommending doxycycline with appropriate caution. When oral antibiotics are used, the guidelines recommend using the lowest effective dose for the shortest necessary duration.
Some dermatologists now use doxycycline as a stepping stone rather than long-term therapy—patients might take it for 3-4 months while their skin adjusts to topical retinoids, then transition off the antibiotic. Others reserve doxycycline primarily for patients with inflammatory acne who genuinely need systemic therapy and have failed topical approaches. This represents evolved practice based on the recognition that frequent, casual antibiotic use harms public health. One important limitation to understand: if a patient has already been prescribed long-term oral antibiotics for acne, switching approaches mid-treatment requires medical guidance. The 2024 guidelines don’t retroactively condemn people already on these medications; instead, they guide future prescribing. Patients shouldn’t stop medications without dermatologist input, but ongoing care should be informed by the updated recommendations.
What the Evidence Gaps Tell Us About Future Research Needs
The 2024 guidelines explicitly acknowledge areas where the evidence base remains insufficient for firm recommendations. Chemical peels, laser therapy, light-based treatments, microneedling, dietary interventions, and botanical products all lack the quality and quantity of research needed to warrant guideline-level recommendations. For some treatments, this reflects genuine lack of research.
For others, it reflects that existing research isn’t methodologically strong enough—perhaps studies were small, poorly controlled, or measured outcomes inconsistently. This gap in evidence is important because it tells dermatologists, patients, and researchers where future work is needed. If someone is interested in studying whether a particular dietary change improves acne, or whether a specific laser wavelength produces better outcomes, the guideline gaps indicate these are legitimate research questions. The absence of a recommendation doesn’t mean a treatment definitely doesn’t work—it means we don’t have sufficient evidence to confidently recommend it as standard care.
How Guidelines Will Continue Evolving
The dermatological field continues advancing rapidly. New topical medications are in development, combination approaches are being researched, and understanding of acne pathophysiology keeps deepening. The 2024 guidelines almost certainly won’t be the final word. In another 7-10 years, the AAD or another organization may publish updated guidance reflecting new evidence. Oral isotretinoin may gain new applications or dosing strategies.
Topical treatments may advance. Or research on procedures like laser therapy might finally accumulate to sufficient quality and quantity to warrant formal recommendations. This ongoing evolution is a feature, not a bug. It means the medical field is responding to new evidence and continuously improving patient care. For patients seeking acne treatment, it’s reassuring to know that guideline recommendations aren’t static dogma—they’re evidence-based guidance that changes as our understanding improves.
Conclusion
The AAD updates its acne management guidelines regularly because skin care science advances continuously, new safety evidence emerges, and dermatologists gain better understanding of what treatments work best for different patients and situations. The 2024 update, published in January, represents the most current evidence-based guidance available. It contains 18 specific recommendations and 5 good practice statements covering topical treatments, oral medications, isotretinoin for severe cases, and acknowledges areas where evidence remains insufficient for formal recommendations. The update also reflects evolved thinking about antibiotic stewardship and resistance, shaping how systemic antibiotics are now recommended.
If you’re dealing with acne, understanding that these guidelines exist and that dermatologists follow them can help you have more productive conversations about treatment. Ask your dermatologist which guideline recommendations they’re following and why a particular treatment is suggested for your specific situation. Guidelines provide the framework, but your dermatologist tailors recommendations to your individual skin, medical history, and needs. Regular guideline updates ensure that framework stays grounded in the best available evidence.
